An unexpected symptom after a cannabinoid exposure deserves attention even when its cause is unclear. Medical care and safety reporting serve different purposes: care addresses the person’s immediate needs, while reporting helps authorities investigate possible patterns. Never delay urgent help to complete a report or to identify the exact substance involved.
Recognise when immediate help is needed
Call 112 for a suspected drug emergency, including unconsciousness, abnormal breathing, seizures, severe chest pain or a rapidly worsening condition. 112 is free throughout the EU, including Ireland and Germany. In Ireland, 999 also reaches emergency services.
The HSE's drug-emergency guidance advises calling even when you are uncertain. Tell the operator your location, what happened and everything known about the exposure. Follow their instructions. Stay with the person if it is safe, monitor breathing, and do not induce vomiting or give other drugs. If the person is unresponsive or not breathing normally, tell the operator immediately so they can guide first aid.
Official NHS poisoning guidance also identifies seizures, unconsciousness and breathing difficulties as emergency warning signs. These signs require action without waiting for certainty about whether a cannabinoid, another substance, or an unrelated condition is responsible.
Symptoms do not identify the cause by themselves
Cannabinoids can be associated with effects such as impaired alertness, dizziness and gastrointestinal symptoms; effects vary by substance. The NCCIH safety overview also discusses drug interactions and uncertainties about the contents of some products. A label alone cannot establish what caused a reaction.
For symptoms that are not an emergency, contact a doctor or pharmacist promptly for individual advice. Describe prescription medicines, non-prescription products and other substances involved. Do not drive while affected. A symptom appearing after exposure is a reason to investigate, rather than proof of a diagnosis or a reason to dismiss an unrelated illness.
Use the appropriate official reporting route
Ireland: The HPRA patient and carer guidance explains how anyone can report a suspected medicine side effect. You do not need certainty that the medicine caused it. A healthcare professional can also help.
Germany: BfArM and the Paul-Ehrlich-Institut provide the official joint medicine side-effect reporting portal. BfArM's annual report confirms that patients and relatives, as well as healthcare professionals, can report.
Other EU countries: Consult the national medicines authority. EMA's patient information explains that EMA does not accept side-effect reports directly from patients.
These are medicine-reporting systems. A non-medicinal cannabinoid product may require a different public-health, food-safety or product-safety route. Ask a healthcare professional or the relevant national authority which system applies; do not assume that every cannabinoid product is an authorised medicine.
Record useful details without delaying care
Keep the packaging and note the product name, batch number if available, exposure date, symptom timeline and any medical assessment. Include other medicines and relevant conditions when making an official report. The HPRA accepts reports with missing details, so incomplete information need not prevent reporting.
Understand what a report means
The EMA patient reporting guide explains that experts review suspected reactions for safety signals. An individual report is a suspicion, not confirmation of causation. Reporting cannot replace treatment, and public report counts cannot by themselves establish how common a reaction is.
Sources
- European Union: Emergency number 112
- HSE: What to do in a drug emergency
- NHS: Poisoning
- NCCIH: Cannabis and Cannabinoids
- HPRA: Reporting as a patient or carer
- BfArM/PEI: Reporting portal
- BfArM: Annual report 2023
- EMA: Frequently asked questions
- EMA: Patient reporting guideline